A detailed history of Jpmorgan Chase & CO transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,304 shares of MCRB stock, worth $1,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,304
Previous 39,443 96.69%
Holding current value
$1,069
Previous $30,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$0.56 - $1.19 $21,357 - $45,385
-38,139 Reduced 96.69%
1,304 $0
Q1 2024

May 10, 2024

SELL
$0.75 - $1.56 $19,929 - $41,453
-26,573 Reduced 40.25%
39,443 $30,000
Q4 2023

Feb 12, 2024

SELL
$0.93 - $2.15 $72,205 - $166,926
-77,640 Reduced 54.05%
66,016 $92,000
Q3 2023

Nov 14, 2023

BUY
$2.33 - $5.07 $8,520 - $18,540
3,657 Added 2.61%
143,656 $341,000
Q2 2023

Aug 11, 2023

SELL
$4.67 - $6.55 $2.26 Million - $3.17 Million
-484,022 Reduced 77.57%
139,999 $670,000
Q1 2023

May 18, 2023

BUY
$4.95 - $6.09 $490,693 - $603,701
99,130 Added 18.89%
624,021 $3.54 Million
Q1 2023

May 11, 2023

SELL
$4.95 - $6.09 $433,907 - $533,837
-87,658 Reduced 14.31%
524,891 $2.98 Million
Q4 2022

Feb 13, 2023

SELL
$5.09 - $9.05 $497,924 - $885,307
-97,824 Reduced 13.77%
612,549 $3.43 Million
Q3 2022

Nov 14, 2022

SELL
$3.5 - $7.2 $246,648 - $507,391
-70,471 Reduced 9.02%
710,373 $4.56 Million
Q2 2022

Aug 11, 2022

BUY
$2.7 - $7.62 $1.72 Million - $4.87 Million
638,779 Added 449.64%
780,844 $2.68 Million
Q1 2022

May 11, 2022

BUY
$6.3 - $8.84 $669,066 - $938,816
106,201 Added 296.12%
142,065 $1.01 Million
Q4 2021

Feb 10, 2022

SELL
$6.02 - $11.43 $3.43 Million - $6.51 Million
-569,573 Reduced 94.08%
35,864 $300,000
Q3 2021

Nov 12, 2021

BUY
$5.46 - $22.6 $3.31 Million - $13.7 Million
605,437 New
605,437 $4.21 Million

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $102M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.